Financing Alternatives for Public Companies
This article was originally published in Start Up
The sudden closing of a stock market window for public offerings is not a happy event for companies caught in the midst of the offering process. So what should a company do in this situation? Advice of Counsel explores financing alternatives.
You may also be interested in...
With the markets down, it's time to explore alternatives to straight equity deals for public companies: PIPEs, equity lines of credit, convertible debt, and "toxic preferred" securities.
Is there an explanation for the recent spate of biotech Phase II and Phase III clinical trial failures? It's almost impossible to give general reasons for specific clinical failures. Several hypotheses, borrowed from the tenets of behavioral finance, however, may help explain some recent, unanticipated later-stage setbacks. They may also support other studies that suggest that small biotech companies fail more often in clinical development than their larger biotech and pharma brethren.
Venture-backed biotech companies are increasingly seeking to commercialize drugs that qualify for orphan drug protection from the FDA; is this business model a good idea?